Pathology-Targeted EP4 Agonism Reverses Fibrosis in a Rat Model of DMD
Nasim Kajabadi, Ashok Narasimhan, Gang Chen, Lin Yi, Cristina Rodríguez‐Rodríguez, Ian F. Coccimiglio, Tiffany Huang, Mariana Manzano Rendeiro, Keitaro Yamanouchi, Urs O. Häfeli, Paul J. Kostenuik, Robert Norman Young, Fabio M V Rossi
This study shows that Irodanoprost, a bone-targeted EP4 agonist, reduces fibrosis and restores muscle regeneration in a rat model of Duchenne muscular dystrophy.
bioRxiv · Jun 2, 2026 · PreprintPharmacology & Toxicology